

A provider guide to helping patients afford Anafranil. Covers discount cards, patient assistance programs, generics, and cost strategies.
You've found the right medication for your patient's OCD. Anafranil (Clomipramine) is working. And then they stop filling the prescription — not because of side effects, but because they can't afford it.
Medication cost is one of the most common — and most preventable — reasons patients become non-adherent. For Clomipramine specifically, the gap between retail pricing and what patients can actually pay with the right tools is enormous. This guide gives you practical, actionable strategies to help your patients access affordable Anafranil.
Understanding the cost landscape helps you anticipate barriers before they derail treatment:
The disparity between $600 retail and $15 with a discount card means the difference between adherence and abandonment often comes down to whether someone told the patient about discount programs.
Unlike many brand-name medications, there is no active manufacturer savings card for Anafranil since the brand is largely discontinued in the US. Clomipramine is now primarily available as a generic from multiple manufacturers including Mallinckrodt and Taro.
This actually simplifies the savings conversation — generic discount programs are the primary pathway to affordability.
These programs work at the pharmacy counter and can reduce the cost of generic Clomipramine dramatically:
The most effective approach is making discount card information a standard part of your prescribing process for patients who are uninsured, underinsured, or facing high copays:
For a comprehensive patient-facing guide, direct patients to our post on how to save money on Anafranil.
For patients who can't afford even discounted generic pricing — including those who are uninsured, on fixed incomes, or experiencing financial hardship — patient assistance programs (PAPs) can help:
Patient assistance programs often require paperwork. To reduce friction:
Since Clomipramine is already available as a generic, the "generic alternative" conversation is straightforward — ensure the pharmacy is dispensing generic Clomipramine, not brand Anafranil.
However, if cost remains a barrier even with discount cards, consider whether a therapeutic substitution might be appropriate:
Of course, therapeutic substitution is a clinical decision. If a patient has tried SSRIs without adequate response and is doing well on Clomipramine, switching to save money may not be in their best interest. The goal is to keep them on the medication that works while minimizing cost.
For detailed alternatives, see our clinical comparison at alternatives to Anafranil.
Cost isn't the only barrier — Anafranil has experienced intermittent supply disruptions since 2020. When patients can't find the medication at their pharmacy, they may go without doses, which affects treatment outcomes.
Strategies to help:
For a comprehensive approach to supply issues, see our provider's guide to helping patients find Anafranil in stock.
The most effective cost interventions happen proactively, not after a patient has already abandoned their prescription. Consider these workflow changes:
For more resources on supporting your patients who take Anafranil, visit Medfinder for Providers.
The gap between Clomipramine's retail price ($600/month) and its discounted price ($15-$40/month) represents one of the biggest easy wins in medication adherence. By routinely sharing discount card information, screening for cost barriers, and connecting patients with assistance programs, you can dramatically improve the chances that your patients stay on the medication that's working for them.
The tools exist. The programs exist. The missing link is often just a 30-second conversation at the point of prescribing.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.